We asked four laboratories for a sterility test. Here is what came back.
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Lucía Berenguer
Page 12 of 18 of this archive, newest first.
Archive — page 12
356 piecesWhat changed at QSC in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at ERP in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at CPC in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at QYB in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why TFC can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
What changed at WXT in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What a 35% rise in coupling-reagent prices does to a 10 mg vial
Follow the resin, not the catalogue.
What changed at FGP in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What a 22% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
What changed at FGP in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at SWB in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at WWB in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at SWB in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at WXT in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What changed at WWB in November, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The supplement trade found this drug class quickly, and the citations did not improve
A survey of what the meta-analyses support, with the populations named.
What a 37% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
What a 9% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
What changed at QSC in October, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.